Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1222 participants
INTERVENTIONAL
2011-10-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-label Study of TAK-875
NCT01433419
Double-blind Comparative Study of TAK-875
NCT01433393
Double Blind Comparative Study of TAK-875
NCT01585792
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
NCT00949091
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
NCT01647542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAK-875 25 mg
(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
TAK-875
TAK-875 50 mg
(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
TAK-875
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-875
TAK-875
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria
2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nagoya, Aichi-ken, Japan
Chiba, Chiba, Japan
Funabashi-shi, Chiba, Japan
Katori-shi, Chiba, Japan
Kisarazu-shi, Chiba, Japan
Matsudo-shi, Chiba, Japan
Matsuyama, Ehime, Japan
Nihama-shi, Ehime, Japan
Saijo-shi, Ehime, Japan
Fukuoka, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Onga-gun, Fukuoka, Japan
Annaka-shi, Gunma, Japan
Takasaki-shi, Gunma, Japan
Aki-gun, Hiroshima, Japan
Hiroshima, Hiroshima, Japan
Chitose-shi, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Amagasaki-shi, Hyōgo, Japan
Nishinomiya-shi, Hyōgo, Japan
Mito, Ibaragi, Japan
Naka, Ibaragi, Japan
Tsuchiura-shi, Ibaragi, Japan
Ushiku-shi, Ibaragi, Japan
Sakade-shi, Kagawa-ken, Japan
Izumi-shi, Kagoshima-ken, Japan
Kamakura-shi, Kanagawa, Japan
Yamato-shi, Kanagawa, Japan
Kochi, Kochi, Japan
Suzaki-shi, Kochi, Japan
Kumamoto, Kumamoto, Japan
Minamata-shi, Kumamoto, Japan
Uji-shi, Kyoto, Japan
Miyazaki, Miyazaki, Japan
Matsumoto-shi, Nagano, Japan
Nagasaki, Nagasaki, Japan
Omura-shi, Nagasaki, Japan
Ōita, Oita Prefecture, Japan
Okayama, Okayama-ken, Japan
Izumisano, Osaka, Japan
Kashiwara-shi, Osaka, Japan
Osaka, Osaka, Japan
Sakai-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Toyonaka-shi, Osaka, Japan
Saga, Saga-ken, Japan
Fujimi-shi, Saitama, Japan
Saitama-shi, Saitama, Japan
Sayama-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Ōtsu, Shiga, Japan
Fujinomiya-shi, Shizuoka, Japan
Shizuoka, Shizuoka, Japan
Shimotsuga-gun, Tochigi, Japan
Shimotsuke-shi, Tochigi, Japan
Komatsu-shi, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Hino-shi, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Katsushika-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Nerima-ku, Tokyo, Japan
Ōta-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Sibuya-ku, Tokyo, Japan
Toyoshima-ku, Tokyo, Japan
Sanyoonoda-shi, Yamaguchi, Japan
Shimonoseki-shi, Yamaguchi, Japan
Ube-shi, Yamaguchi, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1124-1561
Identifier Type: REGISTRY
Identifier Source: secondary_id
JapicCTI-111602
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-875/OCT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.